Human IL-33 enzyme-linked immunoassay kit
| Specification | 96 Test |
|---|---|
| Sensitivity | 0.76 pg/ml (50 μl)；1.25 pg/ml (10 μl) |
| Standard Curve Range | 1.37~1000 pg/ml |
| Standard Curve Gradient | 7 Points/3 Folds |
| Number of Incubations | 2 |
| Sample Volume | 50 μl/10 μl |
| Type | Fully Ready-to-Use |
| Operation Duration | 120min |
| pg/ml | O.D. | Average | Corrected | |
|---|---|---|---|---|
| 0.00 | 0.0254 | 0.0268 | 0.0261 | |
| 1.37 | 0.0326 | 0.0317 | 0.0322 | 0.0061 |
| 4.12 | 0.0475 | 0.0402 | 0.0439 | 0.0178 |
| 12.35 | 0.0736 | 0.0732 | 0.0734 | 0.0473 |
| 37.04 | 0.1710 | 0.1730 | 0.1720 | 0.1459 |
| 111.11 | 0.4827 | 0.4851 | 0.4839 | 0.4578 |
| 333.33 | 1.3800 | 1.3950 | 1.3875 | 1.3614 |
| 1000.00 | 3.6260 | 3.6220 | 3.6240 | 3.5979 |
Precision
| Intra-assay Precision | Inter-assay Precision | |||||
| Sample Number | S1 | S2 | S3 | S1 | S2 | S3 |
| 22 | 22 | 22 | 6 | 6 | 6 | |
| Average(pg/ml) | 22.7 | 109.9 | 312.7 | 23.1 | 111.8 | 322.4 |
| Standard Deviation | 1.0 | 3.4 | 14.9 | 1.1 | 1.8 | 7.6 |
| Coefficient of Variation(%) | 4.5 | 3.1 | 4.8 | 4.8 | 1.6 | 2.4 |
Intra-assay Precision (Precision within an assay) Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.
Inter-assay Precision (Precision between assays) Three samples of known concentration were tested six times on one plate to assess intra-assay precision.
Spike Recovery
The spike recovery was evaluated by spiking 3 levels of human IL-33 into health human serum sample. The un-spiked serum was used as blank in this experiment.
The recovery ranged from 99% to 127% with an overall mean recovery of 108%.
Sample Values
| Sample Matrix | Sample Evaluated | Range (pg/ml) | Detectable (%) | Mean of Detectable (pg/ml) |
|---|---|---|---|---|
| Serum | 30 | n.d.-16.51 | 3 | 16.51 |
Serum/Plasma – Thirty samples from apparently healthy volunteers were evaluated for the presence of IL-8 in this assay. No medical histories were available for the donors.
Product Data Sheet
Background: IL-33
IL-33 (Interleukin-33) is released from physically damaged or necrotic cells. It triggers Th2-biased immune cell activation at sites of inflammation as well as regulatory T cell and M2 macrophage expansion. It additionally induces angiogenesis, promotes tumor cell migration and invasion, limits cardiac myocyte hypertrophy, and limits the development of atherosclerotic plaques. IL-33 signals through a receptor complex composed of ST2 and IL-1 RAcP. IL-1 RAcP also associates with IL-1 RI, IL-1 RII, IL-1 R6, and SCF R/c-kit. Soluble isoforms of ST2 and IL-1 RAcP function as decoy receptors that regulate IL-33 bioactivity.
